TILT BIOTHERAPEUTICS

tilt-biotherapeutics-logo

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.

#People #Financial #Website #More

TILT BIOTHERAPEUTICS

Social Links:

Industry:
Apps Biotechnology Health Care

Founded:
2013-01-01

Address:
Helsinki, Southern Finland, Finland

Country:
Finland

Website Url:
http://www.tiltbio.com

Total Employee:
1+

Status:
Active

Total Funding:
28.73 M EUR

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Apache Sitelinks Search Box Microsoft Exchange Online



Current Advisors List

timo-ahopelto_image

Timo Ahopelto Board Member @ TILT Biotherapeutics
Board_member
2014-01-01

arto-linnervuo_image

Arto Linnervuo Board of Directors @ TILT Biotherapeutics
Board_member

tuija-keinonen_image

Tuija Keinonen Chair of the Board @ TILT Biotherapeutics
Board_member

Current Employees Featured

akseli-hemminki_image

Akseli Hemminki
Akseli Hemminki Founder & CEO @ TILT Biotherapeutics
Founder & CEO
2013-04-01

Founder


akseli-hemminki_image

Akseli Hemminki

Investors List

lifeline-ventures_image

Lifeline Ventures

Lifeline Ventures investment in Venture Round - TILT Biotherapeutics

tesi_image

Tesi

Tesi investment in Venture Round - TILT Biotherapeutics

tekes_image

Business Finland

Business Finland investment in Grant - TILT Biotherapeutics

tekes_image

Business Finland

Business Finland investment in Venture Round - TILT Biotherapeutics

easme_image

EASME - EU Executive Agency for SMEs

EASME - EU Executive Agency for SMEs investment in Grant - TILT Biotherapeutics

business-angels-3_image

Business angels

Business angels investment in Seed Round - TILT Biotherapeutics

lifeline-ventures_image

Lifeline Ventures

Lifeline Ventures investment in Seed Round - TILT Biotherapeutics

tekes_image

Business Finland

Business Finland investment in Seed Round - TILT Biotherapeutics

keksintösäätiö_image

Keksintösäätiö

Keksintösäätiö investment in Seed Round - TILT Biotherapeutics

horizon-2020_image

Horizon 2020

Horizon 2020 investment in Seed Round - TILT Biotherapeutics

Official Site Inspections

http://www.tiltbio.com

  • Host name: grid1i.sigmatic.fi
  • IP address: 80.69.161.45
  • Location: Finland
  • Latitude: 60.1717
  • Longitude: 24.9349
  • Timezone: Europe/Helsinki

Loading ...

More informations about "TILT Biotherapeutics" on Search Engine

TILT Biotherapeutics - Crunchbase Company Profile & Funding

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working …See details»

TILT Biotherapeutics Presents Clinical Data on TILT-123 in …

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented …See details»

TILT Biotherapeutics Announces Positive Clinical Data on

Nov 6, 2023 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with …See details»

Next-generation armed oncolytic immunotherapies

TILT Biotherapeutics, a clinical-stage biopharma company, is developing a solution. TILT was founded on the unique discovery from clinical observations that oncolytic adenoviruses potently...See details»

TILT Biotherapeutics Announces Positive Update on its Phase 1 ...

Mar 31, 2022 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with …See details»

TILT Biotherapeutics Announces First US Patient …

Oct 11, 2022 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can...See details»

TILT Biotherapeutics Announces Positive Clinical Data on Lead …

HELSINKI, Finland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer …See details»

TILT Biotherapeutics Announces Positive Clinical Data in …

HELSINKI, Finland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer …See details»

TILT Biotherapeutics Announces over $10 Million Financing to …

Jun 14, 2022 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with …See details»

TILT Biotherapeutics Presents Clinical Data on TILT-123 in

Apr 10, 2024 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with …See details»

Unleashing the curative potential of cancer immunotherapy

Jul 25, 2022 TILT Biotherapeutics is developing a breakthrough oncolytic immunotherapy for treatment for cancer. Advanced solid tumors are currently incurable and limited …See details»

TILT Biotherapeutics Announces Positive Clinical Data in

HELSINKI, Finland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer …See details»

TILT Biotherapeutics Reports Publication on its Oncolytic …

Aug 27, 2021 TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with …See details»

TILT Biotherapeutics Announces First Patient Dosed in Phase

May 15, 2023 Tags. Biotechnology Cancer Oncology Clinical Trials Oncolytic Virus Cytokines. HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT …See details»

TILT Biotherapeutics Awarded USD 2M Grant from US …

HELSINKI, Finland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it …See details»

TILT Biotherapeutics - Funding, Financials, Valuation & Investors

TILT Biotherapeutics has raised a total of. $48.1M. in funding over 9 rounds. Their latest funding was raised on Feb 14, 2024 from a Grant round. TILT Biotherapeutics is …See details»

TILT Biotherapeutics - Contacts, Employees, Board Members, …

About. TILT Biotherapeutics has 1 current employee profile, Founder & CEO Akseli Hemminki. TILT Biotherapeutics has 3 board members and advisors, including Timo …See details»

TILT Biotherapeutics - Tech Stack, Apps, Patents & Trademarks

Mar 10, 2024 About. TILT Biotherapeutics uses 13 technology products and services including HTML5 , jQuery , and Google Analytics, according to G2 Stack. TILT …See details»